EP4702011A1 - Composés antiviraux de 1,3-di-oxo-indène - Google Patents

Composés antiviraux de 1,3-di-oxo-indène

Info

Publication number
EP4702011A1
EP4702011A1 EP24726860.0A EP24726860A EP4702011A1 EP 4702011 A1 EP4702011 A1 EP 4702011A1 EP 24726860 A EP24726860 A EP 24726860A EP 4702011 A1 EP4702011 A1 EP 4702011A1
Authority
EP
European Patent Office
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24726860.0A
Other languages
German (de)
English (en)
Inventor
Young-Sik Jung
Daniel Poon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Korea Research Institute of Chemical Technology KRICT
Original Assignee
Novartis AG
Korea Research Institute of Chemical Technology KRICT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Korea Research Institute of Chemical Technology KRICT filed Critical Novartis AG
Publication of EP4702011A1 publication Critical patent/EP4702011A1/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne des composés de 1,3-dioxoindène tels que décrits dans la description, ainsi que des sels pharmaceutiquement acceptables, des compositions pharmaceutiques contenant de tels composés, et des procédés d'utilisation de ces composés, sels et compositions pour le traitement d'infections virales.
EP24726860.0A 2023-04-24 2024-04-24 Composés antiviraux de 1,3-di-oxo-indène Pending EP4702011A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363497972P 2023-04-24 2023-04-24
PCT/US2024/025962 WO2024226581A1 (fr) 2023-04-24 2024-04-24 Composés antiviraux de 1,3-di-oxo-indène

Publications (1)

Publication Number Publication Date
EP4702011A1 true EP4702011A1 (fr) 2026-03-04

Family

ID=91129863

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24726860.0A Pending EP4702011A1 (fr) 2023-04-24 2024-04-24 Composés antiviraux de 1,3-di-oxo-indène

Country Status (11)

Country Link
EP (1) EP4702011A1 (fr)
KR (1) KR20260030710A (fr)
CN (1) CN121335890A (fr)
AU (1) AU2024263864A1 (fr)
CO (1) CO2025014569A2 (fr)
DO (1) DOP2025000268A (fr)
IL (1) IL323915A (fr)
MX (1) MX2025012590A (fr)
PE (1) PE20260292A1 (fr)
TW (1) TW202506103A (fr)
WO (1) WO2024226581A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
BR112013032306B1 (pt) 2011-06-16 2021-05-25 Korea Research Institute Of Chemical Technology derivados de indanona, método de preparação dos mesmos, composições farmacêuticas e uso dos mesmos para prevenção ou tratamento de doenças virais
JP7592748B2 (ja) * 2020-04-20 2024-12-02 ノバルティス アーゲー 抗ウイルス1,3-ジ-オキソ-インデン化合物

Also Published As

Publication number Publication date
PE20260292A1 (es) 2026-02-10
CN121335890A (zh) 2026-01-13
KR20260030710A (ko) 2026-03-06
CO2025014569A2 (es) 2026-01-13
MX2025012590A (es) 2025-11-03
TW202506103A (zh) 2025-02-16
WO2024226581A1 (fr) 2024-10-31
DOP2025000268A (es) 2026-01-30
IL323915A (en) 2025-12-01
AU2024263864A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
EP4159211A1 (fr) Composé présentant une activité physiologique telle qu'une activité antivirale
JP2026053472A (ja) 抗ウイルス剤としての官能化ペプチド
US12286423B2 (en) Antiviral 1,3-di-oxo-indene compounds
US20250090491A1 (en) Antiviral 1,3-di-oxo-indene compounds
CN118176202B (zh) 一种含氰基取代的多肽类化合物的晶型及其制备方法
EP4702011A1 (fr) Composés antiviraux de 1,3-di-oxo-indène
TW201700474A (zh) 新的5型磷酸二酯酶抑制劑及其醫藥應用
HK40088484A (zh) 抗病毒素1,3-二氧代茚化合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR